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Localised lymphoma of bone: prognostic factors and treatment
recommendations
A.J. Rathmell, M.K. Gospodarowicz, S.B. Sutcliffe, R.M. Clark & The Princess Margaret
Hospital Lymphoma Group
The Princess Margaret Hospital, Department ofRadiation Oncology, 500 Sherbourne Street, Toronto, Ontario, Canada, M4X
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Summary Twenty seven adult patients with newly diagnosed non-Hodgkin's lymphoma localised to either
bone (Stage IE) or bone and regional lymph nodes (Stage IIE) were treated between 1967 and 1988. Median
age was 53 years and the commonest histology (21 patients) was diffuse histiocytic lymphoma. Twenty-four
patients were treated radically: 15 with radiation therapy (XRT) alone and nine with chemotherapy plus
radiation therapy (CMT). The cause specific survival for these patients was 56% at 5 years and 40% at 10
years. Survival was significantly better for patients treated by CMT (88% at 5 years) as compared to XRT
alone (40% at 5 years, P = 0.03) and for age <60 (72% at 5 years) compared to > 60 (30% at 5 years,
P = 0.018). Relapse-free rate was 27% at 5 years with XRT alone and 89% with CMT (P = 0.01). Risk factors
for loco-regional relapse (seven cases) included: large tumour bulk, treatment by XRT alone and use of
'limited' radiation fields. No radiation dose-response relationship could be identified in this study. Long term
local control and survival for localised lymphoma of bone were excellent after treatment by CMT but XRT
alone was associated with unacceptably high local and distant failure rates.
In Non-Hodgkin's lymphoma, involvement of bone at pres-
entation is relatively uncommon and in the context of
advanced disease it may be impossible to determine if the
lymphoma has arisen primarily within bone or has spread to
bone secondarily. Various definitions of 'primary' lymphoma
of bone have been used but in general the term refers to cases
in which bone involvement occurs as a local or locoregional
presentation of lymphoma, without evidence of disseminated
disease. This presentation accounts for approximately 5% of
all localised extranodal lymphomas (Freeman et al., 1972).
Because of its rarity, most reports of bone lymphoma in the
literature included either small numbers of patients (Menden-
hall et al., 1987; Bacci et al., 1986) or encompassed relatively
long time-scales (Ostrowski et al., 1986; Dosoretz et al.,
1983). These reports incorporated all stages of disease and
multiple therapeutic strategies including surgery alone,
surgery and post-operative XRT, XRT alone, CMT and
chemotherapy alone. Consequently, it has been difficult to
determine the important prognostic factors and optimum
treatment for this condition.
We have previously reported on the patterns ofdisease and
prognostic factors in patients with localised extranodal lym-
phomas treated at Princess Margaret Hospital (PMH) from
1967-1978 (Gospodarowicz et al., 1987). This report
included 14 localised lymphomas of bone out of a total of
226 patients. Our current report examines these 14 patients in
greater detail, as well as a further 13 patients treated between
1979 and 1988. Our objective has been to analyse the prog-
nostic factors, response to treatment and patterns of failure
in this group of patients in order to examine our current
approaches to patients with localised bone lymphoma.
Materials and methods
Patient population
The records of all adult patients registered at PMH with a
diagnosis of malignant lymphoma involving bone from
1967-1988 were reviewed. A total of 57 patients were
identified of which 27 (14 males, 13 females) had localised
disease (stage I and II) and are the subjects of this report.
The median age was 53 years and patients' age ranged from
20 to 88 years. All patients had biopsy-proven NHL arising
in bone. Pathology in all cases was reviewed at PMH at the
time of treatment and classified according to Rappaport
(Rappaport, 1966). The main patients and disease charac-
teristics are summarised in Table I. Pain was the commonest
presenting complaint and the mean duration of symptoms
prior to diagnosis was 14 months. The most frequent site of
presentation was the femur (Figure 1). Six patients had
pathological fractures at presentation. All patients had
abnormal X-rays with a lytic pattern of bone involvement in
20 cases, sclerotic in two cases and mixed in five cases. Based
on the Ann Arbor classification for Hodgkin's disease (Car-
bone et al., 1971), patients were staged as clinical stage IE if
disease was confined to a single bone, and stage IIE if
confined to a single bone plus regional lymph nodes. No
patient in this series had 'B' symptoms. Measurement of
Table I Disease characteristics at presentation, plus relapse and
survival status of radically treated patients after median follow up of
11.2 years
Patients Numbers
Stage:
IE 23
IIE 3
Histologya
DH 21
DLP 2
NM + NLP 3
Unclassified 1
Bulk:
< 10 cm 19
>10cm 8
Relapsesb
locoregionalc 7
distant 7
Survival statusb
alive, no evidence of disease 10
died with disease 13
died, no evidence of disease I
'DH = diffuse histiocytic, DLP = diffuse lymphocytic poorly differ-
entiated. NM = nodular mixed, NLP = nodular lymphocytic poorly
differentiated. bRadically treated patients. clncluding primary failure.
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Figure 1 Sites of bone involvement at presentation.
tumour bulk was based on the maximum dimension of the
tumour as determined from clinical and imaging information,
and was categorised as either 10cm or less, or greater than
10cm. Staging investigations performed after diagnosis varied
over the time-course of the study but all patients had a chest
x-ray, 70% had lymphangiography or abdomino-pelvic CT
scan, 70% had a bone marrow biopsy and 70% had a
skeletal survey or isotope bone scan.
Treatment
Three patients (all with Stage I diffuse histiocytic lymphoma)
were treated palliatively due to advanced age and serious
concomitant illness. All radically treated patients received
XRT and nine patients received additional chemotherapy
(pre-XRT in three cases, post-XRT in six cases). The radia-
tion dose for those treated with XRT alone ranged between
30-45Gy (median 4OGy). Patients treated with CMT
received 34-4OGy (median 35Gy), apart from one patient
where the dose was restricted to 25Gy after nine courses of
chemotherapy. The volume irradiated included the whole of
the affected bone in 14 patients. In ten patients, XRT was
restricted to the region of gross disease with a margin of
normal tissue ('limited' XRT). The regional lymph nodes
were treated systematically only in patients with stage II
disease. Chemotherapy schedules varied over the time-course
of this report. The first two patients received CVP (cyc-
lophosphamide, vincristine and prednisone), the following
four patients received C-MOPP or COPP (cyclophos-
phamide, vincristine, procarbazine and prednisone) and the
three most recently treated patients received CHOP or
BACOP (cyclophosphamide, adriamycin, vincristine, pred-
nisone +/- bleomycin). Patients received two to 20 courses
of chemotherapy with a median number of courses being
six.
Because of the difficulties in establishing the exact remis-
sion status of bony lesions, no attempt was made to distin-
guish between those patients who failed to achieve an initial
complete response (CR) and those who relapsed loco-
regionally after initial CR: all were categorised as loco-
regional relapse. Distant relapse was defined only in those
patients with loco-regional control.
Treatment of relapse was not standardised and in view of
the advanced age of many patients was often palliative. One
patient (with loco-regional relapse) was successfully salvaged
with chemotherapy and remains alive and free of disease 20
years later. No patient with distant relapse was successfully
salvaged.
Statistical methods
Survival and relapse-free rates were calculated using the Kap-
lan Meier method (Kaplan et al., 1958) and compared using
the Wilcoxon-Gehan method (Gehan, 1965). The log rank
method was used for multivariate analysis. Cause-specific
survival calculations were adjusted for deaths due to condi-
tions clearly unrelated to the disease process.
Results
The 5 year actuarial survival was 56%, cause-specific survival
56% and relapse-free rate 48%. Ten year results were 37%,
40% and 39% respectively (Figure 2). analysis of possible
prognostic factors including treatment, age, bulk and his-
tology was performed and a significant survival advantage
was shown for those treated by CMT (P = 0.03) and for age
less than 60 years (P = 0.018, Table II). There was a trend
towards inferior survival for patients with bulky disease but
statistical significance was not reached. There were
insufficient numbers of patients with subtypes other than
diffuse histiocytic to assess the effect of histology on prog-
nosis. Multivariate analysis using log rank method adjusting
for the above variables showed a significant survival advan-
tage only for age less than 60 years (P = 0.042).
With respect to the risk of relapse, a significant advantage
was shown for patients treated with CMT (P = 0.01), for age
less than 60 years (P = 0.017) and for bulk 10cm or less
(P = 0.017). With multivariate analysis the impact of bulk
and treatment modality was maintained but age was not
significant. Relapse-free rates according to disease bulk and
treatment modality are shown in Figure 3.
To determine whether the influence of treatment and
tumour bulk on relapse was predominantly via the effect on
loco-regional or on distant relapse, patients were analysed
according to treatment modality and according to whether
the loco-regional failure was within the XRT treatment
volume or marginal. They were further subdivided according
to the extent of the treatment volume (whole bone or
'limited'). Four patients relapsed in-field, three treated by
XRT alone and one by CMT. The mean XRT dose (36.5Gy)
for these patients was similar to the mean dose (36.9Gy) for
the whole group and thus no dose-response relationship was
identified in this study. Three of the in-field recurrences (two
treated with XRT alone and one with CMT) were in-patients
with bulk greater than 10cm giving a 50% local recurrence
rate in the radically treated group with bulk greater than
10cm. A further three patients had marginal recurrences. All
three had been treated with a 'limited' XRT volume. Only
one of the nine patients who received CMT in this study
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Table II Univariate analysis of prognostic factors for cause-specific
survival (CSS), relapse-free rate (RFP), local relapse-free rate
(LRFR) and distant relapse free rate (DRFR) at 5 years
CSS (%) RFR (%) LRFR (%) DRFR (%)
Overalla 56 48 78 66
Treatment
modality:
XTR 40 27 64 42
CMT 88 89 89 100
P value 0.03 0.01 0.107 0.03
Age:
< 60 72 66 73 90
> 60 30 17 78 21
P value 0.018 0.017 0.564 0.001
Bulk:
< 10 cm 64 59 88 67
> 10 cm 33 17 33 50
P value 0.25 0.017 0.005 0.94
aRadical treatment only.
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recurred loco-regionally but, because of the small numbers,
no statistical difference was observed in loco-regional control
for those treated with CMT and XRT (Table II).
Seven patients with loco-regional control relapsed at dis-
tant sites. The site of first relapse was nodal in five of these
and extranodal in two. Only one patient relapsed in bone and
none relapsed in CNS. Six of the seven patients had XRT
alone as initial therapy and only one received CMT. Even
with the small number of patients, the distant relapse rate for
CMT was significantly lower than that for XRT alone (Table
II).
Late complications of therapy in those who achieved
durable loco-regional control were few in number and
generally of minor significance. One patient developed septic
arthritis of the knee 32 months after treatment for a lesion in
the lower femur and a second patient with a lesion in the
same area developed a chronically stiff and painful knee 5
years after treatment. To date there have been no second
malignancies or pathological fractures recorded following
therapy.
Discussion
The first description of malignant lymphoma of bone was
made by Oberling in 1928 (Oberling, 1928) and the first series
was reported by Parker and Jackson in 1939( Parker et al.,
1939). This latter paper described the histological
appearances and clinical course of 17 cases of reticulum cell
sarcoma of bone, highlighting features which distinguished
this condition from other round cell tumours of bone,
especially Ewing's sarcoma. In their series there was a slight
excess of males, the femur was the commonest site of origin,
radiology revealed a mainly lytic pattern of bone destruction
and there was a relatively favourable prognosis after radical
local treatment (42% survived for 10 years after surgery).
Most cases of reticulum-cell sarcoma would now be classified
as either diffuse histiocytic lymphoma (Rappaport, 1966) or
diffuse large-cell lymphoma (NCI working formulation, 1982)
and many reports have now confirmed this to be by far the
commonest form of NHL to affect bone. In contrast to NHL
elsewhere, follicular and diffuse well differentiated lym-
phocytic types rarely present in bone (Clayton et al., 1987;
Mendenhall et al., 1987). The clinical features reported by
Parker and Jackson and the potential for cure in up to 50%
of patients with local therapy have also been reproduced in
subsequent studies (Dosoretz et al., 1983; Shoji et al.,
1971).
In our own series, 5 and 10 year cause-specific survival for
radically treated localised lymphoma of bone was 56% and
40% respectively. These overall figures are similar to
previous reports but when primary treatment consisted of
XRT alone the 5 year cause-specific survival was 40% as
compared to 88% for patients treated with CMT (P = 0.03).
We observed a survival advantage for patients aged less than
60 years and there was a tendency for more of these younger
patients to receive chemotherapy. However, the extent of the
survival advantage for CMT was so great, that age selection
is unlikely to account for all of the effect. Indeed, when
relapse-free rates were compared by multivariate analysis, the
significant effect of treatment modality was maintained
whereas that of age was not. A survival benefit for CMT
over XRT alone has been reported in other studies (Menden-
hall et al., 1987; Bacci et al., 1986), though not everyone has
found such an advantage in adult patients (Ostrowski et al.,
1986). In children the advantage appears to be irrefutable
(Furman et al., 1989; Loeffler et al., 1986). In our study, the
number of patients with histologies other than diffuse his-
tiocytic was small and thus, no apparent influence of his-
tological subtype on survival was seen - a finding consistent
with other reports (Ostrowski et al., 1986). Unlike some
previous reports (Ostrowski et al., 1986; Shoji et al., 1971) we
found no evidence of inferior survival where vertebral or
pelvic bones were involved.
In this report we have looked in some detail at the loco-
regional failures. Previous reports suggested that the loco-
regional relapse rate after XRT alone varies from 14% to
43% (Dosoretz et al., 1983; Shoji et al., 1971). Generally the
rate appears to be higher than the 25% usually reported for
localised diffuse histiocytic lymphomas at other sites (Bush et
al., 1977; Fuks et al., 1973). In our own series 20% of those
treated by XRT alone relapsed within the treatment volume
and a further 20% had marginal loco-regional relapses. Our
results suggest that large disease bulk (present in two out of
three relapses) is an important risk factor for local failure
after XRT alone, a finding in common with our previous
reports of radiation for localised NHL (Gospodarowicz et
al., 1987; Sutcliffe et al., 1985). Doses of XRT reported in
other series have generally been higher with some claims for
a dose response relationship (Dosoretz et al., 1983; Wang et
al., 1968). Our data did not show evidence for such a rela-
tionship and indeed the three patients with in-field failure
after XRT alone all received doses higher than the median of
35Gy. Where XRT alone was employed the importance of
using a large initial radiation volume (with or without a
boost to the main site of disease) to avoid marginal failures
has been clearly shown. Our data further suggested that
loco-regional control was superior for CMT as compared to
XRT alone. Only one out of nine patients treated with CMT
relapsed loco-regionally, compared to six out of 15 treated
with XRT alone, giving a 5 year local relapse-free rate of
89% with CMT compared to 64% at 5 years (48% at 10606 A.J. RATHMELL et al.
years) for XRT alone. Three other recently reported series
have also shown excellent local control in adults treated with
CMT (Susnorwala et al., 1990; Mendenhall et al., 1987; Bacci
et al., 1986). For children, chemotherapy appears to be so
effective that some authors have suggested omitting XRT
completely (Loeffer et al., 1986), though the consequences of
local failure are so great that, to date, this has not become a
widely accepted approach.
Previous publications have not always stated the frequency
of distant relapse in patients achieving loco-regional control,
but where reported, the rate after local therapy alone ranges
from 22-38% (Mendenhall et al., 1987; Wang et al., 1968).
In our own series 58% of the XRT alone group experienced
distant relapse (with loco-regional control) within 5 years of
treatment. In contrast only one of nine patients treated with
CMT developed distant relapse and despite the small
numbers this recurrence rate was significantly lower than for
XRT alone (P = 0.03). This finding is consistent with several
other recent reports (Susnorwala et al., 1990; Bacci et al.,
1986).
Imaging of the primary tumour in this study was by
conventional X-rays and isotope bone scanning. These
modalities tend to underestimate the extent of tumour spread
both along the medullary cavity and in the surrounding soft
tissues when compared to more modern techniques (Salter et
al., 1989). This may account for at least some of the marginal
recurrences seen after the use of 'limited' radiation treatment
volumes and we now believe that all patients should have CT
and preferably also magnetic resonance imaging of the
primary site as part of the initial disease assessment.
In summary, our study suggested that patients treated with
localised lymphoma of the bone treated with XRT alone
have a higher risk of loco-regional relapse than those with
comparable nodal and extranodal lymphomas at other sites,
especially when bulky disease is present. As for (diffuse his-
tiocytic) lymphomas at other sites, we found no evidence of a
significant gain in local control with the use of radiation
doses greater than 35-4OGy (Sutcliffe et al., 1985). A
significant improvement in cause-specific and relapse-free sur-
vival with the use of CMT as compared to XRT alone has
been demonstrated and we feel that this approach should
now be standard therapy. The optimum schedule, timing and
duration of chemotherapy cannot be determined from our
data but other recent reports of treatment for localised lym-
phoma suggest that for small bulk disease three or four
courses of doxorubicin hydrochloride-based chemotherapy
prior to XRT is adequate (Connors et al., 1987; Longo et al.,
1989). For bulky disease, more prolonged chemotherapy
prior to XRT is probably desirable.
The late complication rate in this series was very low with
no cases of osteoradionecrosis or pathological fracture. This
provides further support for the use of moderate radiation
doses, as complication rates, even in adults, appear to be
significantly higher at doses of 45-50Gy or more (Menden-
hall, 1987; Dosoretz, 1983; Stokes, 1983).
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